title: Response to letter, 'immortal time bias in retrospective analysis'.
authors.affiliation: Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
authors.forename: M A
authors.initials: MA
authors.lastname: Dimopoulos
authors.affiliation: Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Swern
authors.affiliation: Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Li
authors.affiliation: Department of Medical Affairs, Celgene Corporation, Summit, NJ, USA.
authors.forename: M
authors.initials: M
authors.lastname: Hussein
authors.affiliation: Department of Drug Safety, Celgene Corporation, Summit, NJ, USA.
authors.forename: L
authors.initials: L
authors.lastname: Weiss
authors.affiliation: Department of Medical Affairs, Celgene Corporation, Summit, NJ, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Nagarwala
authors.affiliation: Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
authors.forename: R
authors.initials: R
authors.lastname: Baz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*